On September 10, CANSINOBIO fell 5.09% in regular trading, trading at 27.12 HKD/share, with turnover of approximately HKD 39.16 million. The decline comes amid broad-based selling pressure across the biotech sector and profit-taking following the stock's sharp rally in recent weeks.

Within the Biotechnology sector, the overall sector weakened notably. Among individual stocks, EVEREST MED fell 7.50%, 3SBIO fell 2.97%, INNOVENT BIO fell 2.39%, AKESO fell 0.89%, and BEONE MEDICINES fell 0.48%. The sector pullback follows the conclusion of national medical insurance negotiations on September 5-6, with market participants adopting a wait-and-see stance on outcomes for key drug products.

CANSINOBIO had experienced a significant run-up since mid-August, surging over 35% on August 20 after Moderna's mRNA cancer vaccine achieved positive Phase III results, followed by an 18% jump on August 26 upon signing an mRNA personalized therapeutic cancer vaccine cooperation agreement with deepGeneAI. The stock posted another 5.47% gain on September 8 on strong interim results showing 43.81% revenue growth and overseas revenue surging 4,724%. The current decline appears to reflect a technical correction from those elevated levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)